PETACH TIKVAH, Israel, March 23, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical-stage biopharmaceutical company announced today that it has signed an agreement with the University of Oxford to conduct a Phase IIa human challenge trial evaluating its intranasal Molecular Nano-Motor...
Hence then, the article about interna therapeutics announces human challenge trial agreement with the university of oxford to advance intranasal mnm sirna sars cov 2 prophylaxis program was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Interna Therapeutics Announces Human Challenge Trial Agreement with the University of Oxford to Advance Intranasal MNM-siRNA SARS-CoV-2 Prophylaxis Program )
Also on site :
- Deye 2026 Frankfurt Distributor & Partner Summit Concludes Successfully
- Labour doesn’t care about protecting countryside, voters say
- Crimson Desert patch 1.00.03 addresses storage issues, Keyboard & mouse controls & more